These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 3879458)

  • 1. Preparation and properties of FabIgG, a chimeric univalent antibody designed to attack tumour cells.
    Stevenson GT; Glennie MJ; Paul FE; Stevenson FK; Watts HF; Wyeth P
    Biosci Rep; 1985; 5(10-11):991-8. PubMed ID: 3879458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric univalent antibodies for treating lymphoid malignancies.
    Stevenson GT; Cole VM; Summerton J; Watts HF
    Med Oncol Tumor Pharmacother; 1984; 1(4):275-8. PubMed ID: 6544904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial experience in treating human lymphoma with a chimeric univalent derivative of monoclonal anti-idiotype antibody.
    Hamblin TJ; Cattan AR; Glennie MJ; MacKenzie MR; Stevenson FK; Watts HF; Stevenson GT
    Blood; 1987 Mar; 69(3):790-7. PubMed ID: 3101763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conjugation of human Fc gamma in closed-hinge or open-hinge configuration to Fab'gamma and analogous ligands.
    Stevenson GT; Anderson VA; Kan KS; Worth AT
    J Immunol; 1997 Mar; 158(5):2242-50. PubMed ID: 9036971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attack on neoplastic cell membranes by therapeutic antibody.
    Stevenson GT
    Mol Cell Biochem; 1989 Nov 23-Dec 19; 91(1-2):33-8. PubMed ID: 2622456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A standardized conversion of IgG antibody to bispecific form with inversely altered affinities for Fcγ-receptors II and III.
    Leong WS; Thomas KA; Chan CH; Stevenson GT
    Mol Immunol; 2011 Feb; 48(5):760-8. PubMed ID: 21196049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thioether-bonded constructs of Fab'gamma and Fc gamma modules utilizing differential reduction of interchain disulfide bonds.
    Kan KS; Anderson VA; Leong WS; Smith AM; Worth AT; Stevenson GT
    J Immunol; 2001 Jan; 166(2):1320-6. PubMed ID: 11145716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59.
    Harris CL; Kan KS; Stevenson GT; Morgan BP
    Clin Exp Immunol; 1997 Feb; 107(2):364-71. PubMed ID: 9030877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human T cells resistant to complement lysis by bivalent antibody can be efficiently lysed by dimers of monovalent antibody.
    Nielsen SU; Routledge EG
    Blood; 2002 Dec; 100(12):4067-73. PubMed ID: 12393711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A chimeric antibody with dual Fc regions (bisFabFc) prepared by manipulations at the IgG hinge.
    Stevenson GT; Pindar A; Slade CJ
    Anticancer Drug Des; 1989 Mar; 3(4):219-30. PubMed ID: 2930624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigenic modulation of lymphocytic surface immunoglobulin yielding resistance to complement-mediated lysis. II. Relationship to redistribution of the antigen.
    Gordon J; Stevenson GT
    Immunology; 1981 Jan; 42(1):13-7. PubMed ID: 6970171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the interaction of antibodies with immunoglobulin idiotypes on neoplastic B lymphocytes: implications for immunotherapy.
    Elliott TJ; Glennie MJ; McBride HM; Stevenson GT
    J Immunol; 1987 Feb; 138(3):981-8. PubMed ID: 2433338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered antibody for treating lymphoma.
    Stevenson GT; Anderson VA; Leong WS
    Recent Results Cancer Res; 2002; 159():104-12. PubMed ID: 11785834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific F(ab'gamma)3 antibody derivatives for redirecting unprimed cytotoxic T cells.
    Tutt A; Greenman J; Stevenson GT; Glennie MJ
    Eur J Immunol; 1991 Jun; 21(6):1351-8. PubMed ID: 1828423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperative mixtures of bispecific F(ab')2 antibodies for delivering saporin to lymphoma in vitro and in vivo.
    French RR; Courtenay AE; Ingamells S; Stevenson GT; Glennie MJ
    Cancer Res; 1991 May; 51(9):2353-61. PubMed ID: 2015599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of surface-bound antibody accompanying the anti-complementary modulation of leukemic B cell immunoglobulin: contrasting effects of antibodies directed against idiotypic and constant regions.
    Gordon J; Anderson VA; Stevenson GT
    J Immunol; 1982 Jun; 128(6):2863-9. PubMed ID: 6804570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenic modulation of lymphocytic surface immunoglobulin yielding resistance to complement-mediated lysis. I. Characterization with syngeneic and xenogeneic complements.
    Gordon J; Robinson DS; Stevenson GT
    Immunology; 1981 Jan; 42(1):7-12. PubMed ID: 6970174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies which react with lymphocyte-lysed target cells and which cross-react with complement-lysed ghosts.
    Ward RH; Lachmann PJ
    Immunology; 1985 Sep; 56(1):179-88. PubMed ID: 4043993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation and characterization of a chimeric CD19 monoclonal antibody.
    Zola H; MacArdle PJ; Bradford T; Weedon H; Yasui H; Kurosawa Y
    Immunol Cell Biol; 1991 Dec; 69 ( Pt 6)():411-22. PubMed ID: 1725979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of antibody isotype on passive serotherapy of lymphoma.
    Denkers EY; Badger CC; Ledbetter JA; Bernstein ID
    J Immunol; 1985 Sep; 135(3):2183-6. PubMed ID: 2862210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.